8-Chlor-5-methyl-11-(N-methylpiperazino)-5H-dibenzo-1,4-diazepin | 5800-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 8-Chlor-5-methyl-11-(N-methylpiperazino)-5H-dibenzo-1,4-diazepin
• 英文别名: 8-chloro-5-methyl-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine；8-Chloro-5-methyl-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine；3-chloro-11-methyl-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzodiazepine
• CAS: 5800-23-7
• 化学式: C₁₉H₂₁ClN₄
• 分子量: 340.856
• InChiKey: XQIPQCHREHNRDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• MULTI-API LOADING PRODRUGS
  申请人：Alkermes Pharma Ireland Limited

  公开号：EP2655314B1

  公开（公告）日：2018-02-07
• 5 HT RECEPTOR MEDIATED NEUROGENESIS
  申请人：Barlow Carrolee

  公开号：US20100009983A1

  公开（公告）日：2010-01-14

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells.
• CONJUGATES OF HUPERZINE AND ANALOGS THEREOF
  申请人：INSERO HEALTH INC.

  公开号：US20150191430A1

  公开（公告）日：2015-07-09

  Compounds and compositions for treating neurodegenerative diseases are described. The compounds include a therapeutic agent covalently linked with huperzine or an analog thereof through a linker. Methods of preparing the compounds are described. Methods of treating a neurodegenerative disease by administering compounds and compositions including a therapeutic agent covalently linked with huperzine or an analog thereof are described. Methods for delivering a therapeutic agent by administering the therapeutic agent covalently linked to huperzine or an analog thereof are described.
• Multi-API Loading Prodrugs
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20160024011A1

  公开（公告）日：2016-01-28

  The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam-amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.
• [EN] NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY<br/>[FR] AGENTS PSYCHOTROPES INNOVANTS PRÉSENTANT UNE ACTIVITÉ DU GLUTAMATE SUR LES RÉCEPTEURS NMDA
  申请人：UNIV RAMOT

  公开号：WO2008050341A2

  公开（公告）日：2008-05-02

  [EN] The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders.
  [FR] L'invention concerne des composés innovants et des compositions pharmaceutiques pour le traitement de maladies ou de troubles psychiques et/ou psychiatriques.